Michigan State University Parkinson Disease Clinical Center

这是密歇根州立大学(MSU)神经病学系申请成为 帕金森病神经保护临床试验联盟的临床中心。这项活动的目的是 临床试验证实了一种或几种神经保护剂延缓病情进展的效果 帕金森病(PD)的一项大型双盲安慰剂对照临床试验。密歇根州立大学的帕金森 疾病临床中心将识别、招募和维持轻度早期PD患者(Hoehn&Yahr&lt；2， 在这项多中心临床试验的试点和第三阶段试验中)。 该建议书记录了优秀的患者招募和留住有经验的患者的潜力 密歇根州立大学的临床工作人员。总的来说，密歇根州立大学的主要调查人员和神经科 平均每年有近700名帕金森病患者就诊，约有125名新帕金森病患者。基于 来自直接图表审查的数据，55%的新患者将满足纳入和排除标准，如果 服用对症药物的患者也包括在内；如果服用对症药物，20%的患者将符合标准 药物被排除在外。大量可能符合条件的病例反映了 密歇根州立大学神经病学系，这是一大片地区的初级和二级转诊的重点 其他神经学家对这种状态的研究相对较少。 密歇根州的中心位置，加上分散的全州医疗 学校校园系统，是最大限度地招募病人的理想选择。与区域建立了关系 神经学家、当地支持团体以及密歇根帕金森基金会，密歇根帕金森基金会是全州首屈一指的PD 支持组织，将加强密歇根州立大学独特的招聘基础。与伊利诺伊大学合作 密歇根州，以及地区神经学家和运动障碍专科提供者，将促进 高效和全面的患者确认。密歇根州立大学在运动障碍方面有专长的神经学家 将登记和跟踪患者。密歇根州立大学之前在大型纵向临床试验方面的经验提供了 在类似的神经病学多中心研究中，在招募、保留和数据获取方面有良好的记录 疾病。密歇根州立大学是成功参与帕金森病的最佳环境 神经保护临床试验。

This is an application for the Michigan State University (MSU) Department of Neurology to become a clinical center in the Parkinson Disease Neuroprotection Clinical Trial consortium. The objective of the this clinical trial is demonstrate the efficacy of one or several neuroprotective agents in slowing the progression of Parkinson Disease (PD) in a large, double blind, placebo-controlled clinical trial. The MSU Parkinson Disease Clinical Center will identify, enroll and maintain patients with mild, early PD (Hoehn & Yahr <2, within 5 years of symptom onset) in the pilot and Phase III trial components of this multicenter clinical trial. This proposal documents the outstanding patient recruitment and retention potential of the experienced clinical staff at MSU. Collectively, the primary investigators and the Department of Neurology at MSU have an average of nearly 700 PD patient visits and see approximately 125 new PD patients per year. Based on data from direct chart review, 55% of the new patients would meet the inclusion and exclusion criteria if patients taking symptomatic medications are included; 20% would meet criteria if those taking symptomatic medications were excluded. The large pool of potentially eligible cases reflects the referral pattern for the Department of Neurology at MSU, which is the focus of primary and secondary referrals from a large area of the state that is relatively underserved by other neurologists. The central location of MSU within the state of Michigan, combined with the dispersed statewide medical school campus system, is ideal for maximal patient recruitment. Established relationships with area neurologists, local support groups and with the Michigan Parkinson Foundation, the premier statewide PD support organization, will enhance the unique recruitment base at MSU. Collaboration with the University of Michigan, as well as regional neurologists and movement disorders subspecialty providers, will foster efficient and comprehensive patient ascertainment. MSU neurologists with expertise in movement disorders will enroll and follow patients. MSU's previous experience with large, longitudinal clinical trials provide a proven track record in recruiting, retention and data acquisition in similar multi-center studies of neurological disease. MSU is an optimum environment highly successful participation in the Parkinson Disease Neuroprotection Clinical Trial.